The Journal of Heart and Lung Transplantation
International Society for Heart and Lung Transplantation.
Brief communication| Volume 20, ISSUE 3, P372-374, March 2001

Download started.


A retrospective assessment of safety, efficacy, and pharmacoeconomics of generic azathioprine in heart-transplant recipients


      Although a generic formulation of azathioprine (AZA) has been available since 1996, safety, efficacy and pharmacoeconomic implications following conversion from Imuran (AZA) to generic AZA in heart-transplant patients remains to be determined. A retrospective, safety and efficacy assessment, in addition to a cost comparison, was performed in 30 heart-transplant patients who had been switched from Imuran to generic AZA. In heart-transplant patients converted from Imuran to generic AZA, no compromise in safety and efficacy, as measured by white blood cell (WBC) count, infections, rejections, malignancies, and hospitalizations was observed. Generic substitution of Imuran results in an annual cost savings of $318 per patient.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The Journal of Heart and Lung Transplantation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Alloway RR. Generic immunosuppressant use in solid organ transplantation. Transplant Proc 1999;31(suppl 3A):2S–5S.

      2. Azathioprine, Product Information, Roxanne Laboratories, Inc, Columbus, Ohio.

      3. Benet LZ. Understanding bioequivalence testing. Transplant Proc 1999;31(suppl 3A):7S–9S.

        • Banahan B.F
        • Kolassa E.M
        A physician survey on generic drugs and substitution of critical dose medications.
        Arch Intern Med. 1997; 157: 2080-2088
        • Murphy J.E
        Generic substitution and optimal patient care.
        Arch Intern Med. 1999; 159: 429-433
      4. Testimony to Institute of Medicine Committee on Medicare Coverage Extensions. Schnitzler, MA, June 18, 1999.